GMAB:NASDAQGenmab A/S Analysis

Genmab (GMAB) trades at $25.39, well below its DCF fair value of $42.93 and the consensus 12‑month target around $38, indicating roughly 45% upside. The stock sits under its 20‑day (25.53) and 50‑day (26.58) moving averages, confirming a short‑term bearish price bias, yet the MACD histogram is positive and the MACD line has crossed above its signal, providing a subtle bullish signal. Momentum is neutral (RSI 48) and volume is trending down, suggesting limited short‑term buying pressure.
Fundamentally, GMAB delivers robust 25% revenue growth, 93% gross margin and a 21% profit margin, while trading at a PE of 19 versus an industry average of 24, positioning it as a value‑rich growth play. The balance sheet shows high leverage (debt‑to‑equity ~94%) but ample cash ($1.5 B) and solid free cash flow. No dividend is paid, and the sector’s regulatory environment remains a key risk. Analyst sentiment is strongly positive (strong‑buy) and market sentiment is at “Extreme Greed,” supporting the upside thesis.